Thrombophilia. Definition –Tendency to develop clots due to predisposing factors that may be genetically determined.

Slides:



Advertisements
Similar presentations
Venous Thrombo-embolism In Pregnancy
Advertisements

Viral vents his frustration with.  What the d-dimer actually measures  Usual applications of d-dimer  Interesting applications of d-dimer  How to.
Acute venous or arterial thrombosis Acute venous or arterial thrombosis Is there an indication for thrombolysis? Baseline labs: CBC, PT, PTT, fibrinogen.
Thromboembolic complications in IBD
1 THROMBOPHILIA. 2 Thrombophilia is technical term for hypercoagulable state Thrombosis (arterial or venous) is produced by a shift in the balance between.
Thrombophilia. Now considered a multicausal disease, with an interplay of acquired and genetic thrombotic risk factors Approximately half of venous thromboembolic.
Increasingly, women who are asymptomatic present in pregnancy with a known thrombophilia, typically detected because of screening following identification.
Pathology of Coagulation I- Deficiency of Coagulation Factors II- II- HYPERCOAGULABLE STATES.
Thrombophilic states. Thrombophilic state is characterized by a shift in the coagulation balance in favour of hypercoagulability – i.e. easier and oftener.
MLAB Coagulation Keri Brophy-Martinez Thrombophilia.
Pathology 430/826 Thrombosis David Lillicrap. Cardiovascular Disease 30% of all deaths in Canada 54% ischemic heart disease 20% stroke 23% heart attack.
Clinical Genetics M. Kent Froberg, MD Purpose This lecture is designed to illustrate two examples of the use of molecular genetics in the clinical.
Common Queries (and hopefully some answers)
Below the Knee DVT and Pregnancy Related Thrombosis Robert Lampman, MD Morning Report July 2009.
Week 7: Fibrinolysis and Thrombophilia Secondary fibrinolysis Secondary fibrinolysis Primary fibrinolysis Primary fibrinolysis Plasminogen Plasminogen.
Venous thromboembolism: how long to treat?
Deep vein thrombosis. Color duplex scan of DVT Venogram shows DVT.
Unprovoked DVT in a young patient
Volume 359: November 6, 2008 Number 19November 6, 2008.
Thrombophilias Sharon Sams. Objectives Overview of etiology of hypercoagulability Available tests Clinical correlation or “What do I do with these results?”
PATHOPHYSIOLOGY OF THROMBOSIS “Virchow’s Triad” 1.Injury to blood vessels Trauma, atherosclerosis, surgery 2.Stasis of blood Immobility, venous incompetence,
Dr Nico Lategan MBChB, MMed (Haematology)
Anti-phospholipid syndrome Clinton Mitchell 5th year Haematology.
Chapter Ten Venous Disease Coalition Hypercoagulability VTE Toolkit.
Management thrombophilia. introduction Twenty percent of maternal deaths in the United States during that period were attributed to PE. Inherited thrombophilias.
Thrombophilia— Hypercoagulable States Gabriel Shapiro, MD, FACP.
HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Intravascular Coagulation.
Chapter 34 Vascular Thrombosis Due to Hypercoagulable States
APPROACH TO BLEEDING DISORDERS. History of Bleeding Spontaneous vs. trauma/surgery-induced Ecchymoses without known trauma Medications or nutritional.
Pulmonary Embolism and Infarction
Disorders of Coagulation and Thrombosis Courtney Bunevich, D.O. October 24, 2007.
Thrombophilia (Hypercoagulable States)
7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines.
Hypercoagulable Syndromes. Risk Factors For Venous Thrombosis ACQUIREDINHERITEDMIXED/UNKNOWN Advancing ageAntithrombin Deficiency  Homocysteine ObesityProtein.
Thrombophilia=Tendency to Thrombosis HEREDITARYACQUIRED.
Tabuk University Faculty of Applied Medical Sciences Department Of Medical Lab. Technology 3 rd Year – Level 5 – AY
Thrombophilia National Haemophilia Director
Hypercoagulation.
Hypercoagulable States. Acquired versus inherited Acquired versus inherited “Provoked” vs idiopathic VTE “Provoked” vs idiopathic VTE Who should be tested.
Thrombophilia (Hypercoagulable States) Abdulkareem Almomen, MD Professor of Medicine & Hematology, King Saud University MED 341, Feb.2014.
Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit.
Welcome Applicants!! Welcome Applicants!! Morning Report Friday, October 28 th.
Venous thromboembolic disease
Bleeding and Kristine Krafts, M.D. Thrombotic Disorders.
Hematology Blueprint PANCE Blueprint. Coagulation Disorders.
Protein C.  Protein C is a major physiological anticoagulant. anticoagulant  It is a vitamin K-dependent serine protease enzyme, that is activated by.
LABORATORY DIAGNOSIS OF PROTHROMBOTIC STATES. REGULATION OF COAGULATION Introduction Coagulation necessary for maintenance of vascular integrity Enough.
Thrombophilia Made Simple for Obstetricians
Deep vein thrombosis and pulmonary embolism.
Management issues in other thrombophilia Ng Heng Joo Department of Haematology Singapore General Hospital.
PULMONARY EMBOLISM BY Dr. Hayam Hebah Associate professor of internal medicine AL-Maarefa College.
PULMONARY EMBOLUS Quick revision guide – Chris Scott.
Hypercoagulable States
Coagulation disorders in pregnancy. Hematological Changes During Pregnancy: 1-Expansion of plasma volume and hemodilution. 2-Hb level increases, but there.
Haemostasis. Indications for hemostasis test – Identify patients presenting with bleeding that have a correctable bleeding tendency – Identify patients.
Hemostasis Is a complex process which causes the bleeding process to stop. It refers to the process of keeping blood within a damaged blood vessel. Dependent.
Approach to the Bleeding Child. Evaluation  History Current Bleeding Medical Family  Physical exam  Selected laboratory investigations.
Treatment of deep venous thrombosis and pulmonary embolism Anders Waage.
Chapter 23. Bleeding disorders associated with coagulopathy
Deficiencies of Proteins C, S and Antithrombin and Activated Protein C Resistance – Their Involvement in the Occurrence of Arterial Thromboses Report PGY.
By : Saad Gharaibeh Anwar Al-Kassar Samah Telfah Abd-elsalam Sleman Venous Thrombo-embolism (VTE) 1.
The antiphospholipid syndrome (APS) is defined by two major components (see 'Classification criteria' below: 'Classification criteria' The occurrence.
Thrombosis.
Dr Ferdous Mehrabian. Dr Ferdous Mehrabian Inherited thrombophilias in pregnancy Inherited thrombophilias is a genetic tendency to venous thrombosis.
Confirmed VTE Treatment Pathway
Bleeding and Thrombotic Disorders Kristine Krafts, M.D.
Thrombophilia.
Inherited thrombophilia Screening
Thrombophilia in pregnancy: Whom to screen, when to treat
Hemostasis and Coagulation
Presentation transcript:

Thrombophilia

Definition –Tendency to develop clots due to predisposing factors that may be genetically determined

Classification –Inherited –Acquired –Inherited + acquired

Inherited Thrombophilia Caused by defective gene –Activated protein C resistance (factor V Leiden)- least severe –Inhibitor deficiencies: protein S, proteinC, antithrombin (intermediate severity) –Prothrombin 20210A allele mutation  hyperprothrombinaemia (v. severe) –Hyperhomocysteinaemia

Inherited defects & thrombophilia

Activated protein C resistance Factor V Leiden –Gene mutation in chromosome 1 –Accounts for most but not all cases of APC resistance –Factor Va unresponsive to protein C –15% of Causasians are carriers –Rare in Asians & Africans heterozygotes 5-10x  risk of clotting homozygotes x  risk

Acquired thrombophilia Antiphospholipid syndrome –lupus anticoagulant: anticoag in vitro, but pro- coag. in vivo –Suspect if : a young person presents with MI, CVA, hepatic vein thrombosis (Budd- Chiari syndome) Recurrent miscarriages Incidental finding of prolonged APTT +  platelets

Drugs Disease states: – Malignancy –connective tissue diseases –myeloproliferative disorders – pregnancy – surgery –trauma

Mixed hereditary + acquired Acquired conditions amplify the risk of clotting in those with underlying hereditary coagulatory defects Examples: oral contraceptives, HRT, pregnancy, surgery

When to suspect thrombophilia +ve family history occlusion at unusual sites e.g. brain, portal veins recurrent thrombosis unexpected VTE unexpected occlusion of arterial tree e.g. young ppl with MI or CVA

Arterial thrombosis –anticoagulation pathway anomalies rarely cause arterial events –Main differentials Antiphospholipid syndrome Hyperhomocysteinaemia Dysfibroginaemia

Evaluation History –VTE or arterial occlusive disease in <50 –Recurrent VTEs Family history- VTE in 1st degree relatives Screen if >1 of the above is +ve

Investigations Screening of population is not justified because overall incidence of thrombosis is low Screen people in whom an occlusive event has occurred and has unusual circumstances e.g. young age, recurrent episodes, family hx

Acute Event No need to investigate fully at this stage Management the same regardless of cause VTE –FBC, blood gas –D-dimer- good -ve predictive valuebut +ve test not specific –CXR –U/S –CTPA

Investigations FBC-  platelets,  RBCs APTT –good for picking up APC resistance –Patient’s plasma + Factor V deficient plasma: v. sensitive & specific for factor V Leiden Thrombin time Lupus anticoagulant, anticardiolipin & antiphospholipid antibodies

Assays for Protein C/ protein S –Antigen level –Functional assay Homocystein level DNA analysis –factor V Leiden –Prothrombin 20210A

Investigations Results affected by: –acute thrombotic event –pregnancy –Disease states: liver, DIC, inflammation, surgery –Drugs: anticoagulants, OCPs

Treatment- Acute Pulmonary Embolism O2 Inotrope support Fluids IV heparin- bolus followed by infusion, then oral warfarin after 24 hrs Thrombolysis - consider in massive PE

Treatment- Acute DVT –below knee TED stockings Re- scan in 7-10 days Anticoagulate if there is progression –above knee- anticoag x 3 months

Treatment- Long term +ve family hx but asymptomatic –Counselling –No action required Anticoagulation (INR ) –1 episode of VTE in the presence of another triggering event months anticoagulation. Stop when triggering factor is gone –VTE without triggering factors- anticoagulant for 6 months, but indefinite if the episode was life-threatening

Indefinite coagulation –> 2 spontaneous thrombotic events –Event AND > 1 hereditary defects –life-threatening thrombotic episode –? Hereditary defect with 1st thrombotic episode- benefit unclear. But yes if patient is heterozygote for antithrombin deficiency (  risk of clotting compared to other herditary conditions). Maybe yes if there is protein C/S defect

IVC filter –consider if patient still has recurrent VTEs despite adequate anticoagulation

Prophylaxis Pre-op LMWH –major op: give for 5-10 days –Aspirin not as effective as LMWH Pregnancy -subcut. LMWH rather than warfarin